Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
CONCLUSION: The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.PMID:36319021 | DOI:10.3899/jrheum.220313 (Source: J Rheumatol)
Source: J Rheumatol - November 1, 2022 Category: Rheumatology Authors: Dhruvkumar Laheru Anna Antony Sueli Carneiro Vito Di Lernia Amit Garg Thorvardur Jon Love Karla Del Rocio Macias Garcia Jos é Alexandre Mendonça Sandeep Mukherjee Rodica Olteanu Lourdes Perez-Chada Cheryl F Rosen Rachel Tannenbaum Michel Alexandre Yazbe Source Type: research
Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
CONCLUSIONS: Cal/BD aerosol foam demonstrated significantly greater efficacy than HP/Taz lotion, and had a more favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam following relapse both had significant advantages over HP/Taz lotion.PMID:36223060 | DOI:10.1007/s13555-022-00824-9 (Source: Pain Physician)
Source: Pain Physician - October 12, 2022 Category: Anesthesiology Authors: David N Adam Marie Y Jablonski Bernasconi Henrik Thoning Jashin J Wu Source Type: research
Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
CONCLUSIONS: Cal/BD aerosol foam demonstrated significantly greater efficacy than HP/Taz lotion, and had a more favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam following relapse both had significant advantages over HP/Taz lotion.PMID:36223060 | DOI:10.1007/s13555-022-00824-9 (Source: Pain Physician)
Source: Pain Physician - October 12, 2022 Category: Anesthesiology Authors: David N Adam Marie Y Jablonski Bernasconi Henrik Thoning Jashin J Wu Source Type: research
